Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer

Biochemical and Biophysical Research Communications

Volumn 303, Issue 4, 2003, Pages 1169-1178

  Zhang, Lin ^a,b   Yang, Nuo ^c   Mohamed Hadley, Alisha ^b   Rubin, Stephen C ^d   Coukos, George ^a,b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Division of Gynecologic Oncology   (United States)

Author keywords

Angiogenesis; Gene therapy; Isoform; Ovarian cancer; RNA interference; VEGF

Indexed keywords

DNA DIRECTED RNA POLYMERASE III; ISOPROTEIN; MESSENGER RNA; RNA DERIVATIVE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DNA VECTOR; DRUG EFFECT; EXPRESSION VECTOR; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; RNA SEQUENCE; SEQUENCE HOMOLOGY;

MURINAE;

EID: 0344211452     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00495-9     Document Type: Article

References (55)

1. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257.
2. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1996;1096-1103.
3. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:2003;203-213.
4. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., Mercurio A.M. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 61:2001;5736-5740.
5. Zhang L., Yang N., Garcia J.R., Mohamed A., Benencia F., Rubin S.C., Allman D., Coukos G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 161:2002;2295-2309.
6. Shima D.T., Kuroki M., Deutsch U., Ng Y.S., Adamis A.P., D'Amore P.A. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 271:1996;3877-3883.
7. Tober K.L., Cannon R.E., Spalding J.W., Oberyszyn T.M., Parrett M.L., Rackoff A.I., Oberyszyn A.S., Tennant R.W., Robertson F.M. Comparative expression of novel vascular endothelial growth factor/vascular permeability factor transcripts in skin, papillomas, and carcinomas of v-Ha-ras Tg.AC transgenic mice and FVB/N mice. Biochem. Biophys. Res. Commun. 247:1998;644-653.
8. Ng Y.S., Rohan R., Sunday M.E., Demello D.E., D'Amore P.A. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev. Dyn. 220:2001;112-121.
9. Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114:2001;853-865.
10. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell. 4:1993;1317-1326.
11. Yuan A., Yu C.J., Kuo S.H., Chen W.J., Lin F.Y., Luh K.T., Yang P.C., Lee Y.C. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. 19:2001;432-441.
12. Oshika Y., Nakamura M., Tokunaga T., Ozeki Y., Fukushima Y., Hatanaka H., Abe Y., Yamazaki H., Kijima H., Tamaoki N., Ueyama Y. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer. Int. J. Oncol. 12:1998;541-544.
13. Tomisawa M., Tokunaga T., Oshika Y., Tsuchida T., Fukushima Y., Sato H., Kijima H., Yamazaki H., Ueyama Y., Tamaoki N., Nakamura M. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur. J. Cancer. 35:1999;133-137.
14. Lee Y.H., Tokunaga T., Oshika Y., Suto R., Yanagisawa K., Tomisawa M., Fukuda H., Nakano H., Abe S., Tateishi A., Kijima H., Yamazaki H., Tamaoki N., Ueyama Y., Nakamura M. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur. J. Cancer. 35:1999;1089-1093.
15. Tokunaga T., Oshika Y., Abe Y., Ozeki Y., Sadahiro S., Kijima H., Tsuchida T., Yamazaki H., Ueyama Y., Tamaoki N., Nakamura M. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer. 77:1998;998-1002.
16. Cohen T., Gitay-Goren H., Sharon R., Shibuya M., Halaban R., Levi B.Z., Neufeld G. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem. 270:1995;11322-11326.
17. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 187:1992;1579-1586.
18. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
19. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
20. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature. 376:1995;66-70.
21. Grunstein J., Masbad J.J., Hickey R., Giordano F., Johnson R.S. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol. Cell Biol. 20:2000;7282-7291.
22. Yu J.L., Rak J.W., Klement G., Kerbel R.S. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res. 62:2002;1838-1846.
23. Guo P., Xu L., Pan S., Brekken R.A., Yang S.T., Whitaker G.B., Nagane M., Thorpe P.E., Rosenbaum J.S., Su Huang H.J., Cavenee W.K., Cheng S.Y. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res. 61:2001;8569-8577.
24. Shaheen R.M., Davis D.W., Liu W., Zebrowski B.K., Wilson M.R., Bucana C.D., McConkey D.J., McMahon G., Ellis L.M. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 59:1999;5412-5416.
25. Holash J., Davis S., Papadopoulos N., Croll S.D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J.P., Daly T., Wiegand S.J., Yancopoulos G.D., Rudge J.S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA. 99:2002;11393-11398.
26. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:1997;4593-4599.
27. Goldman C.K., Kendall R.L., Cabrera G., Soroceanu L., Heike Y., Gillespie G.Y., Siegal G.P., Mao X., Bett A.J., Huckle W.R., Thomas K.A., Curiel D.T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA. 95:1998;8795-8800.
28. Cheng S.Y., Huang H.J., Nagane M., Ji X.D., Wang D., Shih C.C., Arap W., Huang C.M., Cavenee W.K. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA. 93:1996;8502-8507.
29. McManus M.T., Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 3:2002;737-747.
30. Elbashir S.M., Harborth J., Weber K., Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 26:2002;199-213.
31. Hannon G.J. RNA interference. Nature. 418:2002;244-251.
32. Shi Y. Mammalian RNAi for the masses. Trends Genet. 19:2003;9-12.
33. Novina C.D., Murray M.F., Dykxhoorn D.M., Beresford P.J., Riess J., Lee S.K., Collman R.G., Lieberman J., Shankar P., Sharp P.A. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8:2002;681-686.
34. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:2002;243-247.
35. Yu J.Y., DeRuiter S.L., Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA. 99:2002;6047-6052.
36. Sui G., Soohoo C., Affarel B., Gay F., Shi Y., Forrester W.C. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA. 99:2002;5515-5520.
37. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296:2002;550-553.
38. Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conklin D.S. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:2002;948-958.
39. Paul C.P., Good P.D., Winer I., Engelke D.R. Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20:2002;505-508.
40. ′ overhangs efficiently suppress targeted gene expression in mammalian cells Nat. Biotechnol. 20:2002;497-500.
41. Lee N.S., Dohjima T., Bauer G., Li H., Li M.J., Ehsani A., Salvaterra P., Rossi J. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20:2002;500-505.
42. Zeng Y., Wagner E.J., Cullen B.R. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell. 9:2002;1327-1333.
43. McManus M.T., Petersen C.P., Haines B.B., Chen J., Sharp P.A. Gene silencing using micro-RNA designed hairpins. Rna. 8:2002;842-850.
44. Roby K.F., Taylor C.C., Sweetwood J.P., Cheng Y., Pace J.L., Tawfik O., Persons D.L., Smith P.G., Terranova P.F. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 21:2000;585-591.
45. Zhang L., Conejo-Garcia J.R., Yang N., Huang W., Mohamed-Hadley A., Yao W., Benencia F., Coukos G. Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem. Biophys. Res. Commun. 292:2002;860-868.
46. Zhang L., Yang N., Conejo-Garcia J.R., Katsaros D., Mohamed-Hadley A., Fracchioli S., Schlienger K., Toll A., Levine B., Rubin S.C., Coukos G. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin. Cancer Res. 9:2003;264-272.
47. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498.
48. Tuschl T. Expanding small RNA interference. Nat. Biotechnol. 20:2002;446-448.
49. Auersperg N., Wong A.S., Choi K.C., Kang S.K., Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22:2001;255-288.
50. Paddison P.J., Caudy A.A., Hannon G.J. Stable suppression of gene expression by RNAi in mammalian cells. Proc. Natl. Acad. Sci. USA. 99:2002;1443-1448.
51. Ilves H., Barske C., Junker U., Bohnlein E., Veres G. Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study. Gene. 171:1996;203-208.
52. Hasuwa H., Kaseda K., Einarsdottir T., Okabe M. Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett. 532:2002;227-230.
53. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA. 100:2003;183-188.
54. Tiscornia G., Singer O., Ikawa M., Verma I.M. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA. 110:2003;1844-1848.
55. ′ -ends of siRNAs Antisense Nucleic Acid Drug Dev. 12:2002;301-309.